Sanofi And GSK’s Much-Delayed COVID-19 Vaccine Ready To File, But Role Looks Limited

Solid Data But No Advantages Over mRNA Jabs

 
• By Andrew McConaghie

Tipped as one of the most likely to succeed back in early 2020, the delayed development of the adjuvanted protein-based COVID-19 vaccine been humbling for both companies.

GSK Sanofi
Sanofi began developing its vaccine in February 2020, and joined forces with GSK two months later, but setbacks have badly delayed its filing. • Source: Alamy

More from Clinical Trials

More from R&D